HUTCHMED (NASDAQ:HCM) said the acceptance also triggers a milestone payment from partner AstraZeneca (NASDAQ:AZN), which markets Tagrisso, also known as osimertinib. Orpathys, also known as ...

Mary Guan, General Manager of AstraZeneca China Oncology Business. "Through our partnership with HUTCHMED, we are advancing ORPATHYS® to address resistance to EGFR-TKIs[1], unlocking new ...

Savolitinib was launched and is marketed under the brand name ORPATHYS® by our partner, AstraZeneca, for this patient population, representing the first selective MET inhibitor approved in China.

Savolitinib, marketed in China under the brand name ORPATHYS®, is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) jointly developed by AstraZeneca and HUTCHMED with ...